Thromb Haemost 2007; 98(01): 138-147
DOI: 10.1160/TH06-09-0510
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

Molecular characterization of human B domain-specific anti-factor VIII monoclonal antibodies generated in transgenic mice

Géraldine Lavigne-Lissalde*
1   1CNRS UMR 5160, Centre de Pharmacologie et Biotechnologie pour la Santé, Faculté de Pharmacie, Montpellier, France
2   Groupe Hospitalo-Universitaire CHU Carémeau, Nîmes, France
,
Sébastien Lacroix-Desmazes*
3   Institut National de la Santé et de la Recherche Médicale (INSERM), Unité (U) 681, Paris, France
4   Université Pierre et Marie Curie (UPMC – Paris 6), Centre de recherche des Cordeliers, Institut Fédératif de Recherche (IFR) 58, Paris, France
,
Bharath Wootla
3   Institut National de la Santé et de la Recherche Médicale (INSERM), Unité (U) 681, Paris, France
4   Université Pierre et Marie Curie (UPMC – Paris 6), Centre de recherche des Cordeliers, Institut Fédératif de Recherche (IFR) 58, Paris, France
,
Catherine Tarrade
1   1CNRS UMR 5160, Centre de Pharmacologie et Biotechnologie pour la Santé, Faculté de Pharmacie, Montpellier, France
,
Jean-François Schved
5   Hôpital Universitaire Saint-Eloi, Montpellier, France
,
Srini V. Kaveri
3   Institut National de la Santé et de la Recherche Médicale (INSERM), Unité (U) 681, Paris, France
4   Université Pierre et Marie Curie (UPMC – Paris 6), Centre de recherche des Cordeliers, Institut Fédératif de Recherche (IFR) 58, Paris, France
,
Claude Granier
1   1CNRS UMR 5160, Centre de Pharmacologie et Biotechnologie pour la Santé, Faculté de Pharmacie, Montpellier, France
,
Sylvie Villard-Saussine
1   1CNRS UMR 5160, Centre de Pharmacologie et Biotechnologie pour la Santé, Faculté de Pharmacie, Montpellier, France
› Institutsangaben

Financial support: This work was supported by the Institut National de la Santé et de la Recherche Médicale (INSERM), by the Centre National de la Recherche Scientifique (CNRS), by the Université Pierre et Marie Curie-Paris 6, and by grants from Bayer Healthcare (Puteaux, France), Wyeth (Paris la Défense, France), Baxter (Maurepas, France) and LFB (Les Ulis, France). BW is the recipient of a fellowship from LFB.
Weitere Informationen

Publikationsverlauf

Received 11. September 2006

Accepted after resubmission 03. April 2007

Publikationsdatum:
29. November 2017 (online)

Preview

Summary

The development of antibodies directed against factorVIII (FVIII) represents a major hurdle in the treatment of hemophilia A. Most anti-FVIII antibodies are identified through their ability to inhibit the FVIII procoagulant activity. Many of them, however, do not interfere with the functional properties of FVIII. Antibodies directed against the B domain belong to this latter category. Here, we characterized B domain-specific human monoclonal Abs (mAbs) at the molecular level. A series of human mAbs directed against FVIII was produced upon immunization of transgenic XenoMouse mice with human recombinant FVIII (rFVIII). Selection of the hybridoma with epitope specificity for the B domain was performed by differential recognition of full-length and B domain-deleted rFVIII. None of the anti-B domain mAbs demonstrated inhibitory activity against FVIII. Three of the mAbs recognized linear epitopes: mAb 25H3 bound to the 1014HIDGPSLLIEN1024 sequence; mAbs 8E3 and 22B6 shared the same epitope, composed of residues 1534KWNEANR1540. The corresponding soluble peptides inhibited the binding of their respective mAbs to FVIII. mAbs 8E3 and 22B6 displaced the binding of FVIII to vonWillebrand factor. Moreover, some of them (in particular mAbs 4G6 and 8E3) were able to compete for binding to the B domain with the anti-FVIII Abs from hemophilia A patients without inhibitor or with low Bethesda titers. Further investigation will allow to better characterize their clinical relevance.

* These authors contributed equally.